	US 11,866,501 B2
	Anti-TrkB antibodies
Rolf Herrmann, Biberach (DE); Remko Alexander Bakker, Biberach an der Riss (DE); Sebastian Bandholtz, Schemmerhofen (DE); Peter Michael Benz, Veitshoechheim (DE); Michael Dziegelewski, Newburgh, NY (US); Lore Katharina Florin, Redwood City, CA (US); Cynthia Hess Kenny, Pearl River, NY (US); Sarah Kathleen Low, Carmel, NY (US); Holger Rosenbrock, Mittelbiberach (DE); Sanjaya Singh, Blue Bell, PA (US); Heiko Friedrich Stahl, Biberach (DE); Sathyadevi Venkataramani, Blue Bell, PA (US); Vladimir H. Voynov, Danbury, CT (US); and Haiguang Xiao, Ridgefield, CT (US)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Aug. 26, 2020, as Appl. No. 17/002,907.
Application 17/002,907 is a division of application No. 16/002,058, filed on Jun. 7, 2018, granted, now 10,793,634.
Claims priority of application No. 17175122 (EP), filed on Jun. 9, 2017.
Prior Publication US 2020/0399378 A1, Dec. 24, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 27/02 (2006.01); A61P 25/28 (2006.01)

CPC C07K 16/2863 (2013.01) [A61P 25/28 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61P 27/02 (2018.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

1 Claim

1. A method for treatment of a subject suffering from eye disease, comprising:

administering to the subject a therapeutically effective amount of an anti-TrkB antibody or the antigen-binding fragment thereof comprising:

I.a. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 48 (L-CDR1); the amino acid sequence of SEQ ID NO: 49 (L-CDR2); and the amino acid sequence of SEQ ID NO: 50 (L-CDR3); and

I.b. a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 51 (H-CDR1); the amino acid sequence of SEQ ID NO: 52 (H-CDR2); and the amino acid sequence of SEQ ID NO: 53 (H-CDR3), or

I.c. a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 55 (H-CDR1); the amino acid sequence of SEQ ID NO: 56 (H-CDR2); and the amino acid sequence of SEQ ID NO: 57 (H-CDR3), or

I.d. a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 58 (H-CDR1); the amino acid sequence of SEQ ID NO: 59 (H-CDR2); and the amino acid sequence of SEQ ID NO: 60 (H-CDR3), or

administering to the subject a therapeutically effective amount of an anti-TrkB antibody or the antigen-binding fragment thereof comprising:

II.a. a variable light chain and a variable heavy chain comprising the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 12, respectively, or

II.b. a variable light chain and a variable heavy chain comprising the amino acid sequences of SEQ ID NO: 3 and SEQ ID NO: 13, respectively, or

II.c. a variable light chain and a variable heavy chain comprising the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 14, respectively, or

II.d. a variable light chain and a variable heavy chain comprising the amino acid sequences of SEQ ID NO: 5 and SEQ ID NO: 15, respectively, or

II.e. a variable light chain and a variable heavy chain comprising the amino acid sequences of SEQ ID NO: 6 and SEQ ID NO: 16, respectively, or

II.f. a variable light chain and a variable heavy chain comprising the amino acid sequences of SEQ ID NO: 7 and SEQ ID NO: 17, respectively, or

II.g. a variable light chain and a variable heavy chain comprising the amino acid sequences of SEQ ID NO: 8 and SEQ ID NO: 18, respectively, or

II.h. a variable light chain and a variable heavy chain comprising the amino acid sequences of SEQ ID NO: 9 and SEQ ID NO: 19, respectively, or

II.i. a variable light chain and a variable heavy chain comprising the amino acid sequences of SEQ ID NO: 10 and SEQ ID NO: 20, respectively, or

administering to the subject a therapeutically effective amount of an anti-TrkB antibody or the antigen-binding fragment thereof comprising:

III.a. a light chain comprising the amino acid sequence of SEQ ID NO: 21 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 22 or 23, or

III.b. a light chain comprising the amino acid sequence of SEQ ID NO: 24 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 25 or 26, or

III.c. a light chain comprising the amino acid sequence of SEQ ID NO: 27 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 28 or 29, or

III.d. a light chain comprising the amino acid sequence of SEQ ID NO: 30 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 or 32, or

III.e. a light chain comprising the amino acid sequence of SEQ ID NO: 33 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 34 or 35, or

III.f. a light chain comprising the amino acid sequence of SEQ ID NO: 36 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 or 38, or

III.g. a light chain comprising the amino acid sequence of SEQ ID NO: 39 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 40 or 41, or

III.h. a light chain comprising the amino acid sequence of SEQ ID NO: 42 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 43 or 44, or

III.i. a light chain comprising the amino acid sequence of SEQ ID NO: 45 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 46 or 47,

wherein the eye disease is geographic atrophy, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinitis pigmentosa, inherited retinal dystrophy, inherited macular dystrophy, myopic degeneration, retinal vein occlusions, retinal artery occlusions, endophthalmitis, uveitis, cystoid macular edema, choroidal neovascular membrane secondary to any retinal diseases, optic neuropathies, glaucoma, retinal detachment, toxic retinopathy, radiation retinopathy, or traumatic retinopathy.